前列癃闭通胶囊对大鼠前列腺增生影响的实验研究

目的观察前列癃闭通胶囊对大鼠前列腺增生的影响, 为临床中药治疗前列腺增生提供依据。方法取SD雄性2个月龄大鼠30只, 完全随机分成正常对照组、模型组和前列癃闭通治疗组各10只。 应用去势大鼠皮下注射丙酸睾丸酮诱导前列腺增生, 观察正常对照组、模型组、前列癃闭通组大鼠前列腺的湿重、前列腺指数、酸性磷酸酶的变化。结果前列癃闭通组大鼠前列腺的湿重（375±58）mg、前列腺指数（1.68±0.22）和酸性磷酸酶（5.6±1.2）均明显低于模型组［湿重：（419±53）mg; 前列腺指数： 2.11±0.19;酸性磷酸酶：（8.2±1.3）U/L］,差异有统计学意义（P〈0. 01）,并接近正常组的数值［湿重：（321±20）mg;前列腺指数： 1.08±0.12;酸性磷酸酶：（5.1±0.1）U/L］。结论前列癃闭通胶囊可明显抑制大鼠前列腺增生, 抑制大鼠血清酸性磷酸酶水平升高,临床上可以利用中药前列癃闭通胶囊治疗良性前列腺增生症。     

前列腺特异性抗原与性激素及酸性磷酸酶对前列腺的影响

目的　探讨前列腺特异性抗原 (PSA)与性激素及酸性磷酸酶 (PAP)在不同年龄组与前列腺体积的变化关系。方法　通过放射免疫分析检测了血清PAP、性激素 (睾酮、促黄体生成激素 )与血清PSA的含量 ,分析了四种指标随增龄变化及对前列腺体积的影响。结果　血清PAP含量随增龄而增高。血清睾酮 (T)含量随增龄下降 ,对照组 ( 2 0～ 3 9)岁睾酮含量为 ( 8.67± 3 .2 5 )ng/ml ,>40岁各组与之比较均明显降低。血清促黄体生成激素 (LH)含量进行性增高。血清PSA含量各年龄组均波动于同一水平上。结论　血清PAP和促黄体生成激素与前列腺体积呈极为显著的正相关关系 ,睾酮的变化亦相反 (r=-0 .45 ,P <0 .0 1)。PAP含量与前列腺体积无关 ,不受年龄影响。     

补中益气汤对吗啡戒断大鼠前列腺指数和血清性激素的影响

目的:观察补中益气汤对吗啡戒断大鼠前列腺指数和血清性激素的影响。方法:用40只成年♂Wistar大鼠皮下定量递增注射吗啡5d,建立吗啡依赖大鼠模型。d6停止注射吗啡,观察大鼠的戒断反应。自d7开始,除正常对照组和吗啡戒断组外,实验组每天分别给予不同剂量的补中益气汤(2.5,5,10ml·kg-1,ig)。5周后测定大鼠血清睾酮和雌激素水平;摘取前列腺,称体重及前列腺湿重,计算前列腺指数。结果:不同剂量的补中益气汤明显降低吗啡戒断大鼠前列腺湿重、前列腺指数和血清睾酮水平,有升高大鼠血清雌二醇的作用,中剂量(5ml·kg-1)和大剂量(10m·lkg-1)作用明显(P<0.01)。结论:补中益气汤可明显降低吗啡戒断大鼠前列腺指数,且呈剂量依赖关系;明显降低吗啡戒断大鼠血清睾酮水平,有升高大鼠血清雌二醇的作用。补中益气汤抑制吗啡戒断大鼠前列腺组织增生的作用与血清性激素水平变化有关。     

白花败酱草提取物对小鼠前列腺增生的实验研究

目的 研究白花败酱草提取物（PVJE）对小鼠前列腺增生的抑制作用.方法 小鼠随机分为对照组、模型组、普乐安组、小剂量PVJE组、大剂量PVJE组.对照组皮下注射花生油溶液0.1 ml/只,其余各组均皮下注射丙酸睾酮溶液5mg（kg·d）,同时普乐安组给予5 g/（kg·d）的普乐安溶液灌胃,小剂量PVJE组、大剂量PVJE组分别给予0.02、0.04g/（kg·d）的白花败酱草提取物溶液灌胃,共给药12d.研究小鼠前列腺湿重、前列腺指数、性激素水平和光镜下前列腺形态学的变化.结果 与模型组比较,PVJE能明显抑制由丙酸睾丸酮诱发的小鼠前列腺增生,小鼠血清睾丸酮（T）、和雌二醇（E2）含量明显降低.结论 PVJE对丙酸睾丸酮所致小鼠前列腺增生具有显著的拮抗作用.     

GSK3β抑制剂氯化锂对大鼠前列腺增生的影响

目的：探讨 GSK3β抑制剂氯化锂在大鼠前列腺增生治疗中的作用。方法通过皮下注射丙酸睾酮的方法复制前列腺增生模型,建模大鼠随机分成3组：氯化锂高剂量治疗组、低剂量治疗组和模型对照组,另设正常对照组。高剂量和低剂量治疗组分别以20mg／（ kg· d）、10mg （kg· d）的剂量腹腔注射氯化锂,连续给药30d。称量各组大鼠前列腺组织湿重、体积,计算前列腺指数;酶联免疫法测定血清中睾酮（T）、雌激素（E2）和性激素结合球蛋白（SHBG）含量。结果氯化锂治疗组的前列腺湿重、体积和脏器系数较模型对照组显著降低（P＜0．01）;氯化锂治疗组的T、E2和SHBG水平也较模型对照组降低（P＜0．05）。结论 GSK3β抑制剂氯化锂对前列腺增生具有一定抑制作用。     

大鼠前列腺增生模型的研究及药物干预

目的探讨建立一种可靠简便的大鼠良性前列腺增生(BPH)模型。方法采用雄激素法导致大鼠前列腺增生的模型,以前列腺湿/干重、精囊腺湿重、前列腺相对湿/干重、精囊腺相对湿重、前列腺特异性酸性磷酸酶(PCAP)活力及前列腺组织形态学变化为评价指标,并用特异性Ⅱ型5α-还原酶竞争抑制剂-非那雄胺片进行治疗,来验证该模型的可靠性。结果模型组前列腺湿/干重、精囊腺湿重、前列腺相对湿/干重、精囊腺相对湿重均明显高于正常对照组(P<0.01),PCAP活力显著升高(P<0.01),组织形态学变化明显;非那雄胺片能明显改善前列腺增生各指标(P<0.01)。结论该模型制作简便、可靠,稳定性高,可用于良性前列腺增生的研究和药物的筛选。     

前列腺疾病患者血清TPSA、FPSA和PAP的检测及其意义

为探讨总前列腺特异性抗原 (TPSA)、游离前列腺特异性抗原 (FPSA)、前列腺酸性磷酸酶 (PAP)的检测对前列腺疾病的诊断价值 ,采用双抗体夹心酶联免疫 (ELISA)法对 3 8例前列腺癌、85例前列腺良性疾病和 40例正常人血清中 TPSA、FPSA和PAP水平进行了检测。结果显示 ,前列腺癌患者血清中 TPSA、 FPSA和 PAP水平均显著高于前列腺良性疾病组和正常对照组 (P<0 .0 1) ,F/ T比值前列腺癌组明显低于前列腺良性疾病组和正常组 (P<0 .0 1) ,前列腺良性疾病组与正常组无明显差别。     

血清PSA、PAP联合检测对前列腺癌的诊断价值及雌激素对其的影响

目的 研究血清PSA、PAP联合检测对前列腺癌诊断的价值及雌激素对其的影响.方法 选取本院泌尿外科收治的前列腺癌患者60例,给予己烯雌酚3 mg,每日一次口服,同时给予阿司匹林肠溶缓释片100 mg,每日一次口服,连续2个月.同时选取前列腺增生患者60例,正常对照组为同时期体检健康者60例.采用放射免疫分析法,分别观察前列腺增生组、正常对照组、前列腺癌组治疗前、前列腺癌组治疗后血清PSA、PAP水平,以及前列腺癌组患者治疗前后IPSS评分指标.结果 ①前列腺癌组的血清PSA、PAP水平为(80.64±64.72)、(45.86±55.73) ng/ml,明显高于前列腺增生组的(5.82±5.96)、(1.35±0.92) ng/ml和正常对照组的(0.75±0.24)、(0.79±0.61) ng/ml,差异有统计学意义(P＜0.05);前列腺增生组和正常对照组比较差异无统计学意义(P＞0.05).②PSA对前列腺癌的阳性检出率及检测的灵敏性为78.33％,指标特异性达70.00％,而PAP对前列腺癌的阳性检出率及检测的灵敏性为53.33％,指标特异性达93.33％;PSA对前列腺癌检出的阳性率和灵敏性均高于PAP,而特异性却不及PAP,差异有统计学意义(P＜0.05);③治疗后,前列腺癌组血清PSA、PAP水平为(9.71±10.38)、(7.82±11.77) ng/ml,与治疗前比较,血清PSA、PAP水平明显下降,差异有统计学意义(P＜0.05);④治疗后,前列腺癌组前列腺症状有所改善,IPSS评分为(7.68±1.12),与治疗前的(21.66±4.61)比较,IPSS评分明显降低,差异有统计学意义(P＜0.05).结论 血清PSA、PAP联合检测能够提高对前列腺癌诊断的灵敏性和特异性,可用于前列腺癌的早期诊断;雌激素能够降低其水平,改善前列腺癌症状,抑制病情进展.     

血清PSA联合PAP检测提高前列腺癌诊断率的临床应用价值探讨

目的:探讨血清前列腺特异性抗原(PSA)联合酸性磷酸酶(PAP)检测对前列腺癌患者的诊断价值。方法:采用化学发光分析法对96例诊断为前列腺癌的患者、48例前列腺增生患者以及48例正常男性的血清PSA,PAP进行测定。结果:PSA检出前列腺癌的灵敏性为93.75%,特异性为72.38%;PAP对前列腺癌的灵敏性为70.83%,特异性为89.11%。结论:PSA对前列腺癌的疗效监测和筛选诊断有较大的价值,而PAP不适合用于前列腺癌的筛检,PSA可以完全替代PAP对前列腺癌的疗效和预后的监视作用;但PSA联合PAP检测能够有效提高前列腺癌的诊断率以及鉴别前列腺癌与前列腺增生的准确性,具有较大的临床应用价值。     

参桂提取物对实验性前列腺增生大鼠尿动力学的影响

目的 研究参桂提取物对大鼠实验性前列腺增生的治疗作用。方法将60只SD大鼠随机分为6组，每组10只。除假手术组外，其他5组大鼠均在无菌条件下行去势手术，术后1周分别皮下注射溶于橄榄油的丙酸睾丸酮，以制作前列腺增生模型。随后模型对照组给予0.9%氯化钠溶液，5 mL·kg 1；阳性对照组给予普乐安片，2.5 g·kg 1；参桂提取物低、中、高剂量组分别给予参桂提取物0.38 ，0.75和1.50 g·kg 1。假手术组给予假手术后，每天给予0.9%氯化钠溶液0.5 mL。所有大鼠均连续给药4周，末次给药后1 h称重，进行大鼠尿动力学测定，称取前列腺湿重和干重，计算湿重和干重指数。结果参桂提取物高、中剂量组大鼠每日以1.50和0.75 g·kg 1参桂提取物灌胃给药，连续4周后可抑制丙酸睾丸酮引起的大鼠前列腺增生，尿动力学参数明显改善，尿程延长，尿量增加，剩余尿量减少，排尿阈值压均有下降(P＜0.01或P＜0.05)；与模型组比较，前列腺湿重、湿重指数、干重及干重指数均下降（均P＜0.01）。结论参桂提取物可抑制大鼠前列腺增生，明显改善大鼠实验性前列腺增生导致的尿动力学参数。     

Effect of baicalein on experimental prostatic hyperplasia in rats and mice

We determined the effect of baicalein on prostatic hyperplasia in experimental animal models. Prostatic hyperplasia was induced by testosterone propionate in mice and castrated rats and by transplantation of homologous strain fetal mice urogenital sinus in mice. With the histopathological examination, the efficacy of baicalein on prostate hyperplasia in experimental animals was evaluated by the activity of serum acid phosphatase (ACP) and the following norm of the prostate gland: the volume, wet weight, wet weight index, dry weight index, DNA contents and prostatic epithelial height and cavity diameter. Results showed that baicalein at doses of 260 and 130 mg/kg administrated intragastrically (i.g.) significantly inhibited prostatic hyperplasia in castrated rats induced by testosterone propionate compared with the negative control group (p<0.01). Baicalein at doses of 520 and 260 mg/kg (i.g.) also significantly inhibited prostatic hyperplasia in mice induced by transplantation of homologous strain fetal mouse urogenital sinus and by testosterone propionate (p<0.01). These results suggested that baicalein has an inhibitory effect on prostatic hyperplasia in experimental animals.     

Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH) is characterized by hyperplasia of prostatic stromal and epithelial cells, which can lead to lower urinary tract symptoms. The prevalence of BPH increases in an age-dependent manner. We investigated the protective effect of ursolic acid in BPH development using a testosterone-induced BPH rat model. BPH was induced in experimental groups by daily subcutaneous injections of testosterone propionate (TP), for a period of four weeks. Ursolic acid was administrated daily by oral gavage at a dose level of 5 mg/kg during the four weeks of TP injections. Animals were sacrificed on the scheduled termination, before prostates were weighed and subjected to histopathological examination. TP and dihydrotestosterone (DHT) levels in the serum and prostate were also measured. BPH-induced animals displayed an increase in prostate weight with increased testosterone and DHT levels in both the serum and prostate. However, ursolic acid treatment resulted in significant reductions in prostate weight and testosterone and DHT levels in both the serum and prostate, compared with BPH-induced animals. Histopathological examination also showed that ursolic acid treatment suppressed TP-induced prostatic hyperplasia. These findings indicate that ursolic acid may effectively inhibit the development of BPH and it may be a useful agent in BPH treatment.     

Effect of Boerhaavia diffusa in experimental prostatic hyperplasia in rats

Objective:

Present investigation was undertaken to study the effectiveness of hydroalcoholic extract of roots of Boerhaavia diffusa in experimental benign prostatic hyperplasia (BPH) in rats using various animal models.

Materials and Methods:

BPH in rats was induced by subcutaneous injection of testosterone (5 mg/kg) daily for 28 days. Rats were divided in to five groups (six rats each). A negative control group received arachis oil (1 ml/kg s.c.) and four groups were injected testosterone. These four groups were further divided into reference group (finasteride 1 mg/kg), model group (testosterone), study group A (B. diffusa 100 mg/kg), and study group B (B. diffusa 250 mg/kg). On the 29^th day, rats were sacrificed and body weight, prostate weight, bladder weight, and serum testosterone level were measured and histological studies were carried out. Further in vitro analysis of B. diffusa extract on contractility of isolated rat vas deferens and prostate gland, produced by exogenously administered agonists were carried out. All results were expressed as mean ± SEM. 0 Data were analyzed by one-way analysis of variance followed by Tukey''s test.

Results:

B. diffusa (100 mg/kg) treatment for 28 days resulted in significant inhibition of prostate growth (P < 0.05). Drug extract did not have significant change on serum testosterone level. Histopathological analysis of prostate gland supported above results. Results of in vitro experiment suggest that extracts had attenuated the contractile responses of isolated vas deferens and prostate gland to exogenously applied agonists.

Conclusion:

The results suggested that treatment with B. diffusa may improve symptoms of disease and inhibit the increased prostate size. In vitro study implies that herbal extracts has the machinery to produce beneficial effect on prostatic smooth muscle, which would relieve the urinary symptoms of disease. B. diffusa could be a potential source of new treatment of prostatic hyperplasia.KEY WORDS: Benign prostatic hyperplasia, Boerhaavia diffusa, dihydrotestosterone, isolated vas deferens, prostate gland, testosterone     

桂枝茯苓丸对前列腺增生模型小鼠的影响研究

目的:研究桂枝茯苓丸对前列腺增生模型小鼠的影响。方法:ip丙酸睾酮素复制小鼠良性前列腺增生模型。给药组分别ig给予桂枝茯苓丸高、中、低剂量;并用前列康作阳性对照。于末次给药24h后处死动物,取前列腺称量其湿质量,并进行病理学检查。结果:桂枝茯苓丸给药组小鼠前列腺指数均显著低于模型组(P<0.01);病理镜检显示桂枝茯苓丸给药组前列腺减轻,同时可见坏死灶的形成和大量的腺体上皮细胞脱落到腺腔内或凋亡,尤以高、中剂量组最为显著。结论:桂枝茯苓丸可显著抑制小鼠前列腺增生。